UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.
UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.